600624.SHG Shanghai Fudan Forward S&T Co Ltd
- Market cap
- CNY 2.89B
- P/E
- -
- P/B
- 7.04x
- ROE
- -11.8%
- Dividend yield
- 0.42%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600624.SHG undervalued?
Graham numberThe Graham number of Shanghai Fudan Forward S&T Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Fudan Forward S&T Co Ltd fundamental analysis
No fundamental analysis for Shanghai Fudan Forward S&T Co Ltd yet.
Shanghai Fudan Forward S&T Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Fudan Forward S&T Co Ltd
Shanghai Fudan Forward S&T Co., Ltd engages in the medical and health, digital economy, high-tech, and other businesses. The company is involved in the research and development, production, and sales of computer systems, communication equipment, automation instruments, biotechnology, light source lighting, and other products; and import and export business. It also engages in the research and development, production, and sales of chemical raw materials, chemical pharmaceutic…
Full company profileShanghai Fudan Forward S&T Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Fudan Forward S&T Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 671M | 736M | 1.01B | 1.40B | 940M | 1.04B | 789M | 680M | 645M | 640M | 563M |
| Gross Profit | 235M | 320M | 550M | 582M | 427M | 474M | 323M | 263M | 151M | 210M | 180M |
| Operating Income | 45.6M | 53.1M | 63.0M | 54.6M | -26.7M | -61.2M | 3.41M | -1.82M | -132M | -43.4M | -25.6M |
| EBITDA | 114M | 101M | 96.2M | 129M | 2.57M | -21.3M | 48.2M | 56.1M | -76.0M | -132M | -29.4M |
| Net Income | 38.2M | 42.5M | 42.8M | 55.5M | -59.7M | -105M | -6.20M | -21.9M | -133M | -198M | -47.3M |
| EPS | 0.06 | 0.06 | 0.06 | 0.08 | -0.09 | -0.15 | -0.01 | -0.03 | -0.19 | -0.29 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 2.30B | 2.40B | 2.75B | 2.23B | 2.09B | 1.92B | 1.86B | 1.80B | 1.42B | 1.35B | 1.26B |
| Total Liabilities | 1.15B | 1.21B | 1.54B | 1.02B | 971M | 917M | 867M | 952M | 747M | 880M | 822M |
| Shareholders' Equity | 1.09B | 1.12B | 1.14B | 1.13B | 1.04B | 916M | 882M | 805M | 637M | 438M | 399M |
| Cash & Short-term Investments | 384M | 270M | 357M | 297M | 307M | 310M | 309M | 305M | 92.7M | 192M | 127M |
| Total Debt | 539M | 396M | 413M | 387M | 413M | 505M | 516M | 517M | 331M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -26.0M | 96.5M | 126M | 18.6M | 59.0M | 45.6M | 28.1M | 7.03M | -14.4M | -41.1M | - |
| Capital Expenditure | 47.4M | 24.6M | 15.8M | 13.2M | 19.6M | 26.9M | 20.9M | 7.51M | 4.71M | 12.7M | 8.21M |
| Free Cash Flow | -73.4M | 71.9M | 111M | 5.47M | 39.4M | 18.7M | 7.24M | -474K | -19.2M | -53.8M | -66.1M |
| Ratios | |||||||||||
| ROE | 3.5% | 3.8% | 3.7% | 4.9% | -5.7% | -11.5% | -0.7% | -2.7% | -20.9% | -45.1% | -11.8% |
| ROA | 1.7% | 1.8% | 1.6% | 2.5% | -2.9% | -5.5% | -0.3% | -1.2% | -9.4% | -14.6% | -3.8% |
| Net Profit Margin | 5.7% | 5.8% | 4.2% | 4.0% | -6.3% | -10.1% | -0.8% | -3.2% | -20.6% | -30.9% | -8.4% |
| Debt to Equity | 0.49x | 0.35x | 0.36x | 0.34x | 0.40x | 0.55x | 0.58x | 0.64x | 0.52x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Fudan Forward S&T Co Ltd dividends
- Dividend yield
- 0.42%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 3, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 12.3M | 0.02 | - |
| 2024 | CNY 13.9M | 0.02 | - |
| 2023 | CNY 18.0M | 0.03 | - |
| 2022 | CNY 19.4M | 0.03 | - |
| 2021 | CNY 22.3M | 0.03 | - |
| 2020 | CNY 18.5M | 0.03 | - |
| 2019 | CNY 17.1M | 0.02 | 30.8% |
| 2018 | CNY 37.1M | 0.05 | 86.7% |
| 2017 | CNY 40.1M | 0.06 | 94.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on Jul 19, 2016.
Who owns Shanghai Fudan Forward S&T Co Ltd
- Insiders 33.71%
- Institutions 0.00%
- Public & others 66.29%
- Shares outstanding 679M
- Free float 490M
Shanghai Fudan Forward S&T Co Ltd company profile
- Company name
- Shanghai Fudan Forward S&T Co Ltd
- Ticker
- 600624.SHG
- ISIN
- CNE0000006S1
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 15, 1992
- Sector
- Industrials
- Industry
- Pharmaceuticals
- Employees
- 1,355
- Fiscal year end
- December
- Address
- Room 107, Building 2, Shanghai, China, 200433
- Phone
- 86 21 6387 2288
- Website
- forwardgroup.com
About Shanghai Fudan Forward S&T Co Ltd
Shanghai Fudan Forward S&T Co., Ltd engages in the medical and health, digital economy, high-tech, and other businesses. The company is involved in the research and development, production, and sales of computer systems, communication equipment, automation instruments, biotechnology, light source lighting, and other products; and import and export business. It also engages in the research and development, production, and sales of chemical raw materials, chemical pharmaceutical preparations, and traditional Chinese medicine; exporting software to Japan in the fintech sector; and development, construction, operation, and management of high-tech parks. In addition, the company provides investment and consulting services in the high-tech field; distributes car audio and high-end car care products; processes sheet metals; and develops health management systems. Further, it focuses on specialized drugs and specialty, unique drugs; and digestive system drugs, nervous system drugs, anti-tumor drugs, circulatory system drugs, etc., as well as injectable glutathione, shuangyiping tablets, flutamide tablets, bicalutamide tablets, tamoxifen citrate tablets, isosorbide dinitrate tablets, and other products. Shanghai Fudan Forward S&T Co., Ltd was founded in 1984 and is based in Shanghai, China.
Shanghai Fudan Forward S&T Co Ltd management
3- Mr. Zheng SongActing GM & Chairman · born 1969
- Mr. Guo Xiang WenFinancial Officer & Head of Accounting · born 1974
- Mr. Zhou JieBoard Secretary · born 1986